Strategic Buys Fuel MAb Developer Immune Pharma
By Marie Powers
Friday, December 28, 2012
In less than three years, privately held Immune Pharmaceuticals has matured from a start-up launched with a single monoclonal antibody (MAb) licensed from Canada's iCo Therapeutics Inc. into a biotech capable of absorbing the assets of publicly traded EpiCept Corp. in an all-stock deal.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.